Europe Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel

List of Tables

The Europe glaucoma therapeutics market was valued at US$ 1,529.83 million in 2023 and is expected to reach US$ 1,930.78 million by 2031; it is estimated to register a CAGR of 3.0% from 2023 to 2031.

Increasing Number of Product Launches, Collaborations, and Acquisitions Fuels Europe Glaucoma Therapeutics Market

Glaucoma therapeutics manufacturers are implementing strategies such as strategic alliances, geographic expansions, partnerships, mergers & acquisitions, and product/service launches to mark their presence in the market.

In March 2024, MediPrint Ophthalmics, a company that specializes in innovative ocular drug delivery technologies, announced the successful completion of its Phase 2b Glaucoma SIGHT-2 study.

In December 2023, the US Food and Drug Administration (FDA) approved Glaukos Corporation's New Drug Application (NDA) for iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). The drug was approved for a single administration per eye.

In November 2022, Alcon acquired Aerie Pharmaceuticals, Inc. Through the transaction, Alcon acquired Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%; Rhopressa (netarsudil ophthalmic solution) 0.02%; AR-15512, a Phase 3 product candidate for dry eye disease; and a pipeline of several preclinical and clinical ophthalmic pharmaceutical product candidates. Rocklatan and Rhopressa are Rho-kinase inhibitors indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. With this acquisition, Alcon takes a step forward to broaden its portfolio with the inclusion of glaucoma, and retinal and ocular surface disease therapeutics.

In March 2022, Johnson & Johnson Vision Care, Inc. received FDA approval for its new ACUVUE Theravision variant, a type of contact lens containing an antihistamine called ketotifen (19 µg per lens). ACUVUE Theravision with Ketotifen is the first of its kind and is designed to provide a new wearing experience for contact lens users, experiencing allergic eye itch. Such product launches, collaborations, and acquisitions contribute significantly to the growth of the glaucoma therapeutics market.

Europe Glaucoma Therapeutics Market Overview

The Europe glaucoma therapeutics market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy contribute significant shares to the market in this region, and countries such as France, the UK, and Spain are likely to present significant growth opportunities for glaucoma therapeutics market players. The Europe glaucoma therapeutics market growth is ascribed to the rising number of glaucoma cases with the increasing aging population. Germany records a widespread occurrence of glaucoma. According to Sabel Vision Restoration Center (SAVIR), approximately half a million people are affected by glaucoma in this country. However, experts estimate that the actual number may be much higher due to unreported cases. Nearly 10% of all individuals suffering from glaucoma eventually experience serious vision impairments; nonetheless, almost none is likely to attain complete blindness. As per the Federal Statistical Office (Destatis), 16.2 million people in Germany were aged 67 and above by the end of 2021, and the number is projected to rise to 21.6 million by 2060. The probability of developing glaucoma and other eye diseases is likely to increase with aging. Thus, a significant prevalence of glaucoma due to the surging geriatric population propels the demand for glaucoma therapeutics across Germany.

Europe Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

Europe Glaucoma Therapeutics Market Segmentation

The Europe glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the Europe glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the Europe glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the Europe glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the Europe glaucoma therapeutics market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Europe glaucoma therapeutics market.

Product Code: BMIRE00031611

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Europe Glaucoma Therapeutics Market - Key Market Dynamics

4.1 Glaucoma Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Mounting Incidence of Glaucoma Disease
- 4.2.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
4.3 Market Restraints
- 4.3.1 Medication Regimen Compliance Issues
4.4 Market Opportunities
- 4.4.1 Development of Wearable Technologies
4.5 Future Trends
- 4.5.1 Development of Novel Drug Delivery Methods
4.6 Impact of Drivers and Restraints:

5. Glaucoma Therapeutics Market - Europe Analysis

5.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
5.2 Glaucoma Therapeutics Market Forecast Analysis

6. Europe Glaucoma Therapeutics Market Analysis - by Drug Class

6.1 Beta Blockers
- 6.1.1 Overview
- 6.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.2 Alpha Adrenergic Agonists
- 6.2.1 Overview
- 6.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Prostaglandins Analogues
- 6.3.1 Overview
- 6.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Carbonic Anhydrase Inhibitors
- 6.4.1 Overview
- 6.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.5 Combination Drugs
- 6.5.1 Overview
- 6.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Glaucoma Therapeutics Market Analysis - by Indication

7.1 Open Angle Glaucoma
- 7.1.1 Overview
- 7.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Angle Closure Glaucoma
- 7.2.1 Overview
- 7.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Others
- 7.3.1 Overview
- 7.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Glaucoma Therapeutics Market Analysis - by Distribution Channel

8.1 Hospital Pharmacy
- 8.1.1 Overview
- 8.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Retail Pharmacy
- 8.2.1 Overview
- 8.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Online Pharmacy
- 8.3.1 Overview
- 8.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Glaucoma Therapeutics Market - Country Analysis

9.1 Europe
- 9.1.1 Europe: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
  - 9.1.1.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 9.1.1.3 France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 9.1.1.4 United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 9.1.1.5 Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 9.1.1.6 Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 9.1.1.7 Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

10. Glaucoma Therapeutics Market - Industry Landscape

10.1 Growth Strategies in Glaucoma Therapeutics Market
10.2 Organic Growth Strategies
- 10.2.1 Overview
10.3 Inorganic Growth Strategies
- 10.3.1 Overview

11. Company Profiles

11.1 Alcon AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 AbbVie Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Bausch & Lomb Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Viatris Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novartis AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Sun Pharmaceutical Industries Ltd
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Teva Pharmaceutical Industries Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Thea Pharma Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Santen Pharmaceutical Co., Ltd.
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms